Loading...
Market
Story
FDA Approves Rybrevant for Second-Line EGFR-Mutated Lung Cancer, Reducing Progression Risk by Over 50%
Sep 20, 2024, 05:47 AM
Rybrevant (amivantamab-vmjw), in combination with standard of care chemotherapy, has been approved in the U.S. as the first and only targeted regimen for second-line treatment of EGFR-mutated advanced lung cancer. The approval by the FDA is expected to significantly reduce the risk of disease progression by more than 50%. This marks the third new indication for Johnson & Johnson in 2024. The pharmaceutical giant has set a target of $5 billion in sales for Rybrevant, following this approval for EGFR-positive non-small cell lung cancer (NSCLC) with EGFR ex19del/L858R substitution mutations.
View original story
Similar markets
Below $5 billion • 25%
$5 billion to $5.5 billion • 25%
$5.5 billion to $6 billion • 25%
Above $6 billion • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Below $21 billion • 25%
$21 billion to $22 billion • 25%
$22 billion to $23 billion • 25%
Above $23 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Below $7.5 billion • 25%
$7.5 billion to $8 billion • 25%
$8 billion to $8.5 billion • 25%
Above $8.5 billion • 25%
5.7% to 6.2% • 25%
Less than 5.7% • 25%
More than 6.2% • 25%
Other • 25%
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%
Below $27.1 billion • 25%
$27.1 billion to $27.3 billion • 25%
$27.31 billion to $27.5 billion • 25%
Above $27.5 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%